Amato D A, Borden E C, Shiraki M, Enterline H T, Rosenbaum C, Davis H L, Paul A R, Stevens C M, Lerner H J
Invest New Drugs. 1985;3(4):397-401. doi: 10.1007/BF00170765.
Patients with objectively measurable soft tissue sarcoma, bone sarcoma, or mesothelioma who had failed at least one prior chemotherapy regimen received either bleomycin (20 U/M2 i.v. day 1 each week), chlorozotocin (150 mg/M2 i.v. q6 weeks), MGBG (500 mg/M2 i.v. each week, escalated in 50 mg/M2 weekly increments to a maximum dose of 700 mg/M2), or bruceantin (5.5 mg/M2 days 1, 8, 15, and 22, with cycles repeated every 6 weeks). One hundred eighty patients were evaluable: 53 on bleomycin, 51 on chlorozotocin, 38 on MGBG, and 38 on bruceantin. Two partial responses resulted from bleomycin, and one each from chlorozotocin and MGBG. Both responders on bleomycin had mesothelioma. Seventy-four percent of the patients were of ECOG performance status 0 or 1, and over half on each arm had moderate or worse toxicity. At these doses and schedules, none of the four drugs tested was active against previously treated sarcomas. Bleomycin, however, should be considered for further evaluation in mesothelioma patients.
患有客观可测量的软组织肉瘤、骨肉瘤或间皮瘤且至少对一种先前化疗方案治疗失败的患者，接受以下治疗之一：博来霉素（20 U/M²，静脉注射，每周第1天）、氯脲霉素（150 mg/M²，静脉注射，每6周一次）、甲基乙二醛双（鸟嘌呤）腙（MGBG，500 mg/M²，静脉注射，每周一次，以每周增加50 mg/M²的幅度递增至最大剂量700 mg/M²）或鸦胆子素（5.5 mg/M²，第1、8、15和22天给药，每6周重复一个周期）。180例患者可进行评估：53例接受博来霉素治疗，51例接受氯脲霉素治疗，38例接受MGBG治疗，38例接受鸦胆子素治疗。博来霉素治疗产生2例部分缓解，氯脲霉素和MGBG各产生1例部分缓解。接受博来霉素治疗的2例缓解患者均患有间皮瘤。74%的患者ECOG体能状态为0或1，各治疗组中超过半数的患者有中度或更严重的毒性反应。在这些剂量和给药方案下，所测试的四种药物均对先前治疗过的肉瘤无活性。然而，博来霉素应考虑在间皮瘤患者中进行进一步评估。
